Skip to content

Massachusetts · Nonprofit

RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION

RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION (Massachusetts) receives grants from 8 organizations whose IRS filings report $35,181 to it, the largest being DONOR ADVISED CHARITABLE GIVING INC ($10,000). 0 of them have funded it in more than one year.

Revenue FY2024
$12k
Funders on record
8
Grants received
$35k
Net assets
$50k
0/8 repeat funderspeak grant-dependency 11%
01What it does

What Rare Disease Renegades a Nj Nonprofit Corporation does

Mission

Fundraising for scientific research

As stated on its FY2024 Form 990-EZ.

Program

  1. Engaged with and educated the public about rare disease research. 250+ people

    $7,428 spent
    100% of program spending

The program described on its FY2023 Form 990-EZ. Program spending in total: $7,428.

02The organization over time

The organization over time

Each line starts at 100 in 2022, so what you read is the shape rather than the size: 150 means half as much again as 2022, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.

100 = 20222022 Revenue 100 ($105k) Expenses 100 ($53k) Net assets 100 ($53k)2023 Revenue 85 ($89k) Expenses 6 ($3k) Net assets 262 ($139k)2024 Revenue 11 ($12k) Expenses 191 ($101k) Net assets 94 ($50k)
202220232024
Revenue (11)Expenses (191)Net assets (94)Peer revenue range

Balance sheet

Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $139k to $50k (−64%).

$53k
$139k
$50k
202220232024
Total assetsTotal liabilities

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

2022
2023
2024
ContributionsProgram revenueInvestmentOther

100% of RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION’s revenue is contributions — more reliant on donations than three-quarters of its peers (100% for the typical peer).

This organization
Typical peer · 12,214 orgs

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 1 of the last 3 reported years ran a deficit.

$53k
’22
$86k
’23
−$89k
’24

Leadership and staff

Chief executive

William Lester

Executive Director

Board chair

Joelle Lester

Board Member - Chair

As listed on its FY2023 Form 990-EZ.

03Who funds it

Who funds it, year by year

2022 → 2023: the base broadened from 2 funders to 4 funders, grant income fell $10k → $10k.

3 of 8 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 43% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.

From the IRS filings of RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION leans on a few funders — its largest provides 28% of grant income and the top three 76%; half comes from just 2 funders.

the vertical line marks half of all grant income — 2 funders to its left

91% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION.

28%
largest funder
76%
top three
~4
effective funders

Largest funder’s share by year: 2022 98% · 2023 68% — diversifying over time.

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

Where its funders are

RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION draws 100% of its grant income from funders outside Massachusetts, across 3 states in all.

OH
NJ
FL

In-state vs out-of-state, by year

’22
’23
Massachusetts out of state home

Funder states come from each funder’s own filing. $15k arriving through sponsors registered in 3 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

04Its place in the field

Against its field

RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION's revenue fell 89% between 2022 and 2024.

Operating margin−762% · bottom quartile
Revenue growth (annualized)−67% · bottom quartile

this organization peer median middle 50% of peers· 9,898 health nonprofits under $100k, FY2024

Organizations like RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION

Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.

In Massachusetts

Nationally

05Profile & governance

Read directly from this organization’s own Form 990, as neutral context.

Screen this organization

A dated, signed PDF of the compliance screen for RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.

A paid feature, included from the $75 plan up. Sign in to download.

Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf

Questions and answers

Who funds RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION?
RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION (Massachusetts) receives grants from 8 organizations whose IRS filings report $35,181 to it, the largest being DONOR ADVISED CHARITABLE GIVING INC ($10,000). 0 of them have funded it in more than one year.
How many funders does RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION have?
IRS filings report 8 organizations giving $35,181 in grants to RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION.
Who is the largest funder of RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION?
DONOR ADVISED CHARITABLE GIVING INC is the largest funder on record, with $10,000 in grants. The full list of funders is on this page.
How can an organization like RARE DISEASE RENEGADES A NJ NONPROFIT CORPORATION find more funders?
Start with the funders already giving here, then look at the foundations that back similar organizations in Massachusetts. The funding by cause and by state pages list the largest funders for a given area and how to approach them.

Play a game about who funds Rare Disease Renegades a Nj Nonprofit →

These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2022–2024), and the filings of 8 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing